Correspondence
Whether to make decisions "on the fly" regarding treatment for SARS-CoV-2 infection
Tomar o no tomar «decisiones en caliente» respecto al tratamiento de la infección por SARS-CoV-2
Read
860
Timeswas read the article
189
Total PDF
671
Total HTML
Share statistics
array:23 [ "pii" => "S2254887420300813" "issn" => "22548874" "doi" => "10.1016/j.rceng.2020.07.002" "estado" => "S300" "fechaPublicacion" => "2020-10-01" "aid" => "1832" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Medicina Interna (SEMI)" "copyrightAnyo" => "2020" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Rev Clin Esp. 2020;220:461-2" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S0014256520301107" "issn" => "00142565" "doi" => "10.1016/j.rce.2020.04.004" "estado" => "S300" "fechaPublicacion" => "2020-10-01" "aid" => "1832" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Medicina Interna (SEMI)" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Rev Clin Esp. 2020;220:461-2" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "es" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Correspondencia</span>" "titulo" => "Tomar o no tomar «decisiones en caliente» respecto al tratamiento de la infección por SARS-CoV-2" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "461" "paginaFinal" => "462" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Whether to make decisions «on the fly» regarding treatment for SARS-CoV-2 infection" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "V. Abril López de Medrano, E. Merino de Lucas, M. Salavert Lletí" "autores" => array:3 [ 0 => array:2 [ "nombre" => "V." "apellidos" => "Abril López de Medrano" ] 1 => array:2 [ "nombre" => "E." "apellidos" => "Merino de Lucas" ] 2 => array:2 [ "nombre" => "M." "apellidos" => "Salavert Lletí" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2254887420300813" "doi" => "10.1016/j.rceng.2020.07.002" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2254887420300813?idApp=WRCEE" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0014256520301107?idApp=WRCEE" "url" => "/00142565/0000022000000007/v1_202009260731/S0014256520301107/v1_202009260731/es/main.assets" ] ] "itemAnterior" => array:19 [ "pii" => "S2254887420300746" "issn" => "22548874" "doi" => "10.1016/j.rceng.2020.05.007" "estado" => "S300" "fechaPublicacion" => "2020-10-01" "aid" => "1861" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Medicina Interna (SEMI)" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Rev Clin Esp. 2020;220:459-61" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Correspondence</span>" "titulo" => "Pulmonary embolism and COVID-19: A paradigm change" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "459" "paginaFinal" => "461" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Tromboembolismo pulmonar y COVID-19: un cambio de paradigma" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "A. Franco-Moreno, N. Muñoz-Rivas, B. Mestre-Gómez, J. Torres-Macho" "autores" => array:4 [ 0 => array:2 [ "nombre" => "A." "apellidos" => "Franco-Moreno" ] 1 => array:2 [ "nombre" => "N." "apellidos" => "Muñoz-Rivas" ] 2 => array:2 [ "nombre" => "B." "apellidos" => "Mestre-Gómez" ] 3 => array:2 [ "nombre" => "J." "apellidos" => "Torres-Macho" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0014256520301405" "doi" => "10.1016/j.rce.2020.05.006" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0014256520301405?idApp=WRCEE" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2254887420300746?idApp=WRCEE" "url" => "/22548874/0000022000000007/v2_202010040643/S2254887420300746/v2_202010040643/en/main.assets" ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Correspondence</span>" "titulo" => "Whether to make decisions "on the fly" regarding treatment for SARS-CoV-2 infection" "tieneTextoCompleto" => true "saludo" => "Dear Director," "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "461" "paginaFinal" => "462" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "V. Abril López de Medrano, E. Merino de Lucas, M. Salavert Lletí" "autores" => array:3 [ 0 => array:4 [ "nombre" => "V." "apellidos" => "Abril López de Medrano" "email" => array:1 [ 0 => "vicente.abril.lopezdemedrano@gmail.com" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "*" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "E." "apellidos" => "Merino de Lucas" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 2 => array:3 [ "nombre" => "M." "apellidos" => "Salavert Lletí" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] ] ] ] "afiliaciones" => array:3 [ 0 => array:3 [ "entidad" => "Consorcio Hospital General Universitario de Valencia, Valencia, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Hospital General Universitario de Alicante, Alicante, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Hospital Universitario y Politécnico La Fe, Valencia, Spain" "etiqueta" => "c" "identificador" => "aff0015" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Tomar o no tomar «decisiones en caliente» respecto al tratamiento de la infección por SARS-CoV-2" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">The outbreak of the COVID-19 pandemic is a challenge of enormous dimensions for healthcare professionals, public health, and politicians.</p><p id="par0010" class="elsevierStylePara elsevierViewall">As of April 5, 2020, official figures revealed that there were 135,032 people infected, 13,055 deaths, and 59,662 patients hospitalized (<a href="https://covid19.isciii.es/">https://covid19.isciii.es/</a>). We lived through convulsive days in which treatment protocols for COVID-19 infection were modified practically daily based on new evidence and the need to optimize the scarce therapeutic arsenal available.</p><p id="par0015" class="elsevierStylePara elsevierViewall">Just three weeks ago, we learned the results of a clinical trial that compared lopinavir/ritonavir to supportive treatment in severe patients hospitalized with COVID-19 infection whose primary outcome was time until clinical improvement.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> The poor overall results in terms of clinical response and mortality led, in just a few hours, to a rare wave of pessimism among the groups of professionals in charge of making decisions in many hospitals. This was reflected in heated discussions via WhatsApp and other forums, leading to the abrupt removal of lopinavir/ritonavir from the treatment protocols of several large centers in our country.</p><p id="par0020" class="elsevierStylePara elsevierViewall">Nevertheless, the result of the information from a trial such as that one must be taken cautiously and analyzed with a critical, rigorous eye. The work suffers from various methodological problems in the design and in patient recruitment related to the urgent nature of the work. The authors themselves recognize these aspects in the discussion. Patient assignment was not blind and the desirable placebo control was not able to be established for patients who did not receive the drug in said study. Likewise, plasma levels of lopinavir/ritonavir were not able to be determined and could have been compromised in critical patients.</p><p id="par0025" class="elsevierStylePara elsevierViewall">On the other hand, the study lacks power for outcomes that are secondary in the design, but which are important, such as mortality. Assuming the same premises as for the principal variable, between 200 and 860 additional patients would have been needed in each arm to demonstrate differences. In addition, although the overall benefit was weak, a close reading allows for observing how the use of lopinavir/ritonavir could point towards a trend in mortality reduction if it is used in the first 12 days. Among patients treated earlier, the primary objective was indeed achieved, with respective mortality of 15% versus 27% in each arm. What’s more, the other secondary aims, such as a stay in the intensive care unit (5 days of difference) and the percentage of patients who developed ARDS (12% versus 24%), were also improved.</p><p id="par0030" class="elsevierStylePara elsevierViewall">In our opinion, the fundamental issue is that patients were treated too late (median of 13 days from onset of symptoms) and in monotherapy. Therefore, although it did not achieve the primary aim, the results indicate that the treated group could progress better. Therefore, it remains to be determined if the use of lopinavir/ritonavir in the earliest phases and/or in combination with other potentially active drugs would benefit patients or not.</p><p id="par0035" class="elsevierStylePara elsevierViewall">Nevertheless, we are aware of the lack of trust that protease inhibitors and their limited in vitro activity generate and in their clinical efficacy in this novel coronavirus and in others (SARS-CoV, MERS-CoV).<a class="elsevierStyleCrossRefs" href="#bib0010"><span class="elsevierStyleSup">2,3</span></a> The controversial results of this study had already in part been anticipated in another Chinese study,<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a> which did not demonstrate a benefit to treatment with lopinavir/ritonavir and abidol. Furthermore, Janssen has reported unpublished data on the inefficacy of darunavir/cobicistat in the treatment of 30 patients with COVID-19.<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a></p><p id="par0040" class="elsevierStylePara elsevierViewall">Even so, while awaiting new evidence or consolidated alternative therapies, it seems prudent to continue using the optimize form of the few drugs we do have available.</p><p id="par0045" class="elsevierStylePara elsevierViewall">In catastrophic times, it is important to keep a cool head and even keel when it comes to making decisions that may determine a patient’s prognosis.</p></span>" "pdfFichero" => "main.pdf" "tienePdf" => true "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as: Abril López de Medrano V, Merino de Lucas E, Salavert Lletí M. Tomar o no tomar «decisiones en caliente» respecto al tratamiento de la infección por SARS-CoV-2. Rev Clin Esp. 2020;220:461–462.</p>" ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:5 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Trial of lopinavir-ritonavir in adults hospitalized with severe covid-19" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "B. Cao" 1 => "Y. Wang" 2 => "D. Wen" 3 => "W. Liu" 4 => "J. Wang" 5 => "G. Fan" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa2001282" "Revista" => array:3 [ "tituloSerie" => "N Engl J Med" "fecha" => "2020" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32222134" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "V.C.C. Cheng" 1 => "S.K.P. Lau" 2 => "P.C.Y. Woo" 3 => "K.Y. Yuen" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Clin Microbiol Rev" "fecha" => "2007" "volumen" => "20" "paginaInicial" => "660" "paginaFinal" => "694" ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "From SARS to MERS, thrusting coronaviruses into the spotlight" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "Z. Song" 1 => "Y. Xu" 2 => "L. Bao" 3 => "L. Zhang" 4 => "P. Yu" 5 => "Y. Qu" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3390/v11010059" "Revista" => array:6 [ "tituloSerie" => "Viruses" "fecha" => "2019" "volumen" => "11" "paginaInicial" => "E59" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30646565" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S1878875018313068" "estado" => "S300" "issn" => "18788750" ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacies of lopinavir/ritonavir and abidol in the treatment of novel coronavirus pneumonia" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C. Jun" 1 => "L. Yun" 2 => "X. Xiuhong" 3 => "L. Ping" 4 => "L. Feng" 5 => "L. Tao" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3760/cma.j.cn311365-20200210-00050" "Revista" => array:3 [ "tituloSerie" => "Chin J Infect Dis" "fecha" => "2020" "volumen" => "38" ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Results from a single center, open label, randomized, and controlled trial conducted at Shanghai Public Health Clinical Center (SPHCC) of darunavir and cobicistat (DRV/c) in treating laboratory-confirmed 30 COVID-19 patients showed that DRV/c was not effective. Available in: <a target="_blank" href="https://www.jnj.com/lack-of-evidence-to-support-darunavir-based-hiv-treatments-for-coronavirus">https://www.jnj.com/lack-of-evidence-to-support-darunavir-based-hiv-treatments-for-coronavirus</a>. [Accessed 6 April 2020]." ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/22548874/0000022000000007/v2_202010040643/S2254887420300813/v2_202010040643/en/main.assets" "Apartado" => array:4 [ "identificador" => "71813" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Correspondence" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/22548874/0000022000000007/v2_202010040643/S2254887420300813/v2_202010040643/en/main.pdf?idApp=WRCEE&text.app=https://revclinesp.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2254887420300813?idApp=WRCEE" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 1 | 0 | 1 |
| 2024 October | 26 | 1 | 27 |
| 2024 September | 18 | 0 | 18 |
| 2024 August | 24 | 0 | 24 |
| 2024 July | 14 | 2 | 16 |
| 2024 June | 9 | 1 | 10 |
| 2024 May | 15 | 0 | 15 |
| 2024 April | 12 | 0 | 12 |
| 2024 March | 15 | 0 | 15 |
| 2024 February | 4 | 0 | 4 |
| 2024 January | 12 | 0 | 12 |
| 2023 December | 17 | 0 | 17 |
| 2023 November | 16 | 0 | 16 |
| 2023 October | 12 | 0 | 12 |
| 2023 September | 19 | 1 | 20 |
| 2023 August | 12 | 0 | 12 |
| 2023 July | 17 | 0 | 17 |
| 2023 June | 18 | 0 | 18 |
| 2023 May | 15 | 3 | 18 |
| 2023 April | 12 | 0 | 12 |
| 2023 March | 27 | 5 | 32 |
| 2023 February | 10 | 1 | 11 |
| 2023 January | 13 | 3 | 16 |
| 2022 December | 15 | 3 | 18 |
| 2022 November | 16 | 1 | 17 |
| 2022 October | 15 | 3 | 18 |
| 2022 September | 15 | 2 | 17 |
| 2022 August | 10 | 4 | 14 |
| 2022 July | 20 | 10 | 30 |
| 2022 June | 14 | 2 | 16 |
| 2022 May | 15 | 4 | 19 |
| 2022 April | 14 | 5 | 19 |
| 2022 March | 20 | 9 | 29 |
| 2022 February | 15 | 5 | 20 |
| 2022 January | 17 | 7 | 24 |
| 2021 December | 10 | 5 | 15 |
| 2021 November | 5 | 4 | 9 |
| 2021 October | 0 | 2 | 2 |
| 2021 September | 1 | 3 | 4 |
| 2021 August | 1 | 4 | 5 |
| 2021 July | 2 | 4 | 6 |
| 2021 June | 0 | 4 | 4 |
| 2021 May | 1 | 4 | 5 |
| 2021 April | 1 | 0 | 1 |
| 2021 March | 5 | 5 | 10 |
| 2021 February | 8 | 3 | 11 |
| 2021 January | 9 | 13 | 22 |
| 2020 December | 10 | 11 | 21 |
| 2020 November | 15 | 12 | 27 |
| 2020 October | 15 | 13 | 28 |
| 2020 September | 63 | 29 | 92 |
| 2020 August | 1 | 1 | 2 |
Show all
